Yoav Mazor

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

Henit Yanai, Lev Lichtenstein, Amit Assa et al. · Clinical Gastroenterology and Hepatology · 2014 · 309 citations

Life Sciences, Immunology, Pharmacology +12

Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

Yoav Mazor, Ronit Almog, Uri Kopylov et al. · Alimentary Pharmacology & Therapeutics · 2014 · 188 citations

Life Sciences, Clinical Sciences, Immunology +17

Elevated red cell distribution width predicts poor outcome in young patients with community acquired pneumonia

Eyal Braun, Erel Domany, Yael Kenig et al. · Critical Care · 2011 · 137 citations · Full text

Veterinary Medicine, Infectious Diseases, Clinical Epidemiology +12

Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis

Bella Ungar, Yoav Mazor, Roni Weisshof et al. · Alimentary Pharmacology & Therapeutics · 2016 · 87 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies

Uri Kopylov, Yoav Mazor, Miri Yavzori et al. · Inflammatory Bowel Diseases · 2011 · 86 citations · Full text

Life Sciences, Immunology, Clinical Immunology +16